Myeloproliferative Disorder Clinical Trial
— PT-1Official title:
A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia
Verified date | January 2017 |
Source | University of Cambridge |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.
Status | Completed |
Enrollment | 1398 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 59 Years |
Eligibility |
Inclusion Criteria: - The proposal is to include as many patients with PT as possible including previously diagnosed patients whether or not they have received treatment. Thus all patients are eligible assuming they meet the diagnostic criteria and they do not have any exclusion criterion (see below). It will be necessary to stratify patients according to their previous treatment. This information will be collected on entry to the study. Informed consent is of course required where there is a change of therapeutic strategy. The diagnostic criteria for primary thrombocythaemia are: - Platelet count > 600x109/l. - No evidence of overt polycythaemia(confirmed by RCM if necessary)or of polycythaemia masked by co-existent iron deficiency. - No Philadelphia chromosome. - Absence of peripheral blood and/or marrow appearances of myelodysplasia, or myelofibrosis. - No known cause of reactive thrombocytosis. Particular care should be taken to exclude iron deficiency in pre-menopausal women. Notes: - In asymptomatic patients, the platelet count should be observed for a period of at least 2 months to confirm >600x109/l, and to allow any cause of reactive thrombocytosis to become overt. - If the PCV is above normal upper limit (that is, males >0.51, females >0.48) or in high normal range in a patient with palpable splenomegaly measure RCM. Iron deficient primary polycythaemia (polycythaemia vera) is strongly suggested if Hb/PCV is normal in the presence of iron deficient red cell changes. In this situation, iron therapy is potentially dangerous. - Exceeding rarely, bcr-abl positive Philadelphia chromosome negative patients present with high platelet counts with little or no elevation in WBC count. The features that suggest it is necessary to examine for bcr-abl, are:- basophilia, left-shift in WBC, granulocyte count >16x109/l, difficulty in controlling platelet count, megakaryocytes of low ploidy (NAP is usually unhelpful). - A normal ESR, CRP or plasma viscosity is useful in excluding a reactive thrombocytosis. - Written informed consent obtained in accordance with NCRI requirements. - Patients with impaired hepatic / renal function are not excluded although the respective biochemical tests should be monitored during therapy and reduced doses of cytoreductive agent should be used, particularly in the case of hydroxyurea and renal dysfunction. Exclusion Criteria: High risk features (any of the following): - Age >or= 60 years - Platelet count > or= 1500x109/l (current or previous) (a) - History of ischaemia, thrombosis or embolic events (including erythromelalgia) (b) - Haemorrhage considered to be related to PT (b) - Presence of hypertension (c)or diabetes (d) - The manufacturers of hydroxyurea state that it should be avoided in pregnancy and in lactating women. Similarly, hydroxyurea should not be prescribed for women when there is doubt about their use of an effective contraceptive method. - Exclude patient from hydroxyurea therapy and, therefore, from the 'intermediate' risk randomisation if the patient has current leg ulcers. Notes on the definition of high risk: - In patients with borderline counts the allocation of a patient to a high risk group based on platelet count alone should rely on at least three samples taken on separate occasions over at least 2 months. - Documentation of previous thrombo-embolic, ischaemic and haemorrhagic events should be given on the patient's entry proforma. - Hypertension is defined as those patients requiring hypotensive therapy. - Diabetes is defined as those patients requiring therapy with a hypoglycaemic agent. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Addenbrooke`s Hospital | Cambridge | Cambs |
Lead Sponsor | Collaborator |
---|---|
University of Cambridge | Cambridge University Hospitals NHS Foundation Trust, Institute of Cancer Research, United Kingdom |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Does hydroxyurea reduce thrombosis and major haemorrhage when added to aspirin? | Reducing thrombosis and major haemorrhage are specific key measurements in this group of patients for whom thrombotic events are very likely to occur. | 14 years | |
Secondary | Does treatment modality alter the risk of leukaemic or myelofibrotic transformation? | 14 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06246006 -
Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia
|
||
Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
Completed |
NCT03734601 -
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
|
Phase 2 | |
Completed |
NCT00683046 -
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT03149055 -
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
|
Phase 2 | |
Completed |
NCT01866839 -
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
|
Phase 1/Phase 2 | |
Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
Completed |
NCT00588666 -
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03480360 -
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
|
Phase 3 | |
Completed |
NCT00539695 -
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
|
Phase 2 | |
Recruiting |
NCT03869476 -
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
|
N/A | |
Completed |
NCT03688490 -
Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms
|
||
Active, not recruiting |
NCT03434730 -
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
|
Phase 2 | |
Recruiting |
NCT03852407 -
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
|
Phase 2 | |
Completed |
NCT01499147 -
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
|
N/A | |
Completed |
NCT00533923 -
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
|
Phase 2 | |
Active, not recruiting |
NCT04473911 -
Haplo Peripheral Blood Sct In GVHD Prevention
|
Phase 1 | |
Completed |
NCT00909467 -
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
|
N/A | |
Completed |
NCT00687414 -
Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders
|
||
Recruiting |
NCT03808805 -
Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
|
Phase 3 |